The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.
暂无分享,去创建一个
[1] C. Porta,et al. Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. , 2019, European urology.
[2] B. Melichar,et al. Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC) , 2019, Annals of Oncology.
[3] W. Rathmell,et al. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. , 2019, The Lancet. Oncology.
[4] C. Porta,et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial , 2019, The Lancet.
[5] X. Mu,et al. Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). , 2019, Journal of Clinical Oncology.
[6] Ronald C. Chen,et al. PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). , 2019, Journal of Clinical Oncology.
[7] T. Powles,et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[8] R. Motzer,et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.
[9] C. Porta,et al. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. , 2019, Future oncology.
[10] K. Bensalah,et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[11] J. Reeves,et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.
[12] Jing Yan,et al. Targeting VEGF/VEGFR to Modulate Antitumor Immunity , 2018, Front. Immunol..
[13] J. Roszik,et al. mTOR at the Transmitting and Receiving Ends in Tumor Immunity , 2018, Front. Immunol..
[14] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[15] T. Choueiri,et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] P. Subedi,et al. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras , 2015, Cancer medicine.
[17] N. Rioux-Leclercq,et al. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.
[18] R. Motzer,et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. , 2014, The New England journal of medicine.
[19] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[20] C. Tangen,et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.